Edition:
United States

EnteroMedics Inc (ETRM.PH)

ETRM.PH on Philadelphia Stock Exchange

0.24USD
11:53am EDT
Change (% chg)

$0.00 (+0.72%)
Prev Close
$0.23
Open
$0.24
Day's High
$0.24
Day's Low
$0.24
Volume
472
Avg. Vol
1,057
52-wk High
$5.18
52-wk Low
$0.20

Summary

Name Age Since Current Position

Mark Knudson

66 2016 Non-Executive Chairman of the Board

Dan Gladney

55 2015 President, Chief Executive Officer, Director

Gregory Lea

62 2016 Chief Financial Officer, Chief Compliance Officer

Scott Shikora

2015 Executive Vice President - Medical Affairs and Chief Medical Officer

Nick Ansari

54 2016 Senior Vice President - Sales

Paul Hickey

51 2016 Senior Vice President - Marketing and Reimbursement

Peter Delange

46 2016 Senior Vice President - Operations and Business Development

Adrianus Donders

61 2005 Senior Vice President - Research and Advanced Development

Katherine Tweden

54 2015 Senior Vice President - Research

Tonya Dowd

2015 Vice President - Reimbursement

Anthony Jansz

54 2011 Director

Lori McDougal

2015 Director

Catherine Friedman

55 2007 Independent Director

Carl Goldfischer

56 2004 Independent Director

Bobby Griffin

77 2006 Independent Director

Nicholas Teti

63 2007 Independent Director

Jon Tremmel

69 2009 Independent Director

Biographies

Name Description

Mark Knudson

Dr. Mark B. Knudson, Ph.D., is Non-Executive Chairman of the Board of the Company., effective January 1 , 2016. He is no longer Chairman of the Board of the Company., effective December 31, 2015. He is no longer President, Chief Executive Officer of EnteroMedics Inc., since December 2002. Dr. Knudson also served as President and Chief Executive Officer of Venturi Group, LLC and Venturi Development, Inc., positions he held from 1999 and 2001 until their dissolutions in 2008 and 2009, respectively. Dr. Knudson served as Chairman of the Board of Restore Medical, Inc., a publicly-held medical device company focused on the treatment of sleep disordered breathing, from 1999 through July 2008 when it was acquired by Medtronic, Inc. Dr. Knudson was also a member of the audit committee of Restore Medical. Dr. Knudson received a Bachelor of Science in biology from Pacific Lutheran University and a Ph.D. in physiology from Washington State University.

Dan Gladney

Mr. Dan W. Gladney has been appointed as President, Chief Executive Officer, Director of the Company, effective November 16, 2015. Mr. Gladney was most recently a Director and Chief Executive Officer of Lanx, Inc., a medical device company focused on developing and commercializing innovative devices for spinal surgery, which was acquired by Biomet, Inc. in 2013. Prior to Lanx, Mr. Gladney was Healthcare Operating Partner at Norwest Equity Partners (NEP) where he was responsible for strategic planning, business growth and corporate governance for NEP portfolio companies and evaluating and executing new investment opportunities for the firm. Prior to joining NEP, Mr. Gladney served as President and CEO of several successful medical device companies, including Heart Leaflet Technologies (acquired by The Bracco Group) and ACIST Medical Systems (acquired by The Bracco Group). He also served as Chairman, CEO and President of Compex Technologies, a publicly traded orthopedic and health and wellness electro therapy company. Gladney was named in Twin Cities Business Journal's "Top 40 CEO's to Watch" in 2004 and featured on the cover of "Upsize Business Magazine" in 2005 for his noteworthy, collaborative leadership style. He holds a BA from Eastern Michigan University.

Gregory Lea

Mr. Gregory S. Lea is Chief Financial Officer, Chief Compliance Officer of the Company. Mr. Lea also held the title of “Senior Vice President” from May 21, 2007 until December 11, 2014, at which point the title was dropped in order to clarify his position in our executive leadership as a reporting officer for our senior vice presidents. Prior to joining us, Mr. Lea served as Chief Financial Officer of Pemstar Inc. from July 2002 through January 2007 when it was acquired by Benchmark Electronics, Inc. Mr. Lea also served as a director of Pemstar from April 2001 through January 2007 and held the position of Corporate Controller from April 2002 through July 2002. From 1993 to April 2002, Mr. Lea served as a corporate Vice President for Jostens Corporation, a commemorative and affiliation products manufacturer, serving most recently as corporate Vice President-Business Ventures. Prior to that, Mr. Lea held several financial management and administrative positions at IBM Corporation from 1974 to 1993 and was President and a director of Ability Building Center, Inc. from 1981 to 1993. Mr. Lea holds a B.S. in Accounting/Business Management from Minnesota State University, Mankato.

Scott Shikora

Dr. Scott A. Shikora , MD, FACS is Executive Vice President - Medical Affairs and Chief Medical Officer of EnteroMedics Inc. Dr. Shikora has over 20 years of experience in the field of obesity. Currently, he is an Associate Professor of Surgery at Harvard Medical School and the Director of the Center for Metabolic and Bariatric Surgery at Brigham and Women's Hospital in Boston. Prior to that, Scott worked at Tufts Medical Center in Boston for over 16 years, where he was the Director of the Weight and Wellness Center, and Chief of the divisions of Bariatric and General Surgery. He is a member of several medical societies and was active in leadership in the American Society for Parenteral and Enteral Nutrition where he is a past president and former board member. He is past president of the American Society for Metabolic and Bariatric Surgery and a former Executive Council member. Dr. Shikora is Editor-in-Chief of Obesity Surgery and an Associate Editor of the surgical journal Surgery for Obesity and Related Diseases. Dr. Shikora has authored numerous book chapters and journal publications and has made hundreds of presentations internationally on bariatric surgery, new technologies and nutrition support topics. He received his MD from the Columbia University College of Physicians & Surgeons and completed his surgical residency and Nutrition Support fellowship at New England Deaconess Hospital in Boston.

Nick Ansari

Mr. Nick Ansari is Senior Vice President - Sales of the Company. Mr. Ansari joins EnteroMedics with over 20 years in the medical device industry, having held various senior sales positions at Stryker, DePuy, Medtronic, Lanx and Globus Medical. Prior to EnteroMedics, he spent two years as the owner of an independent distributor for Biomet products. Prior to this, he served as Senior Vice President of Sales at Lanx from 2010 to 2013. Mr. Ansari has a strong background in launching new technologies and developing long-term relationships with customers.

Paul Hickey

Mr. Paul Hickey is Senior Vice President - Marketing and Reimbursement of the Company. Mr. Hickey joins EnteroMedics with over 15 years of experience as a medical device executive, most recently having served as Chief Executive Officer of Pantheon Spinal, a small spine implant start-up company based in Austin, Texas , since 2014. Prior to Pantheon, he spent three years as Senior Vice President, Global Commercialization at Lanx, which was acquired by Biomet Spine in 2013, where he oversaw marketing, clinical reimbursement and R&D. Mr. Hickey also spent 17 years at Zimmer-Spine where he held numerous marketing and developments positions, most recently as Vice President, Global R&D and Emerging Technology from 2004-2008.

Peter Delange

Mr. Peter Delange is Senior Vice President - Operations and Business Development of the Company. Mr. Delange has spent the last 11 years as the owner and President of Devicex, a medical devices engineering development company sold in 2015. At Devicex, he contracted with large medical device companies and worked closely with individual surgeons to develop new technologies. Since 2011, Mr. Delange has also served as a Co-Founder and Board Member of FocusStart, an early stage technology development company utilizing a capital efficient business model to advance medical technology. Prior to Devicex, he held software engineer and product development positions at numerous companies including Acist Medical Systems, Nellcor Puritan Bennett, Emerson EMC and Quester Technology.

Adrianus Donders

Mr. Adrianus Donders is the Senior Vice President - Research and Advanced Development of EnteroMedics Inc., since April 2005. From September 2003 to April 2005, Mr. Donders was Director Communication Systems Engineering for Medtronic USA. From June 2000 to August 2003, Mr. Donders served as Director Clinical Study Management and Research and Development Europe for Medtronic Europe. Mr. Donders received a degree equivalent to a Master’s of Electrical Engineering from the Institute of Technology Eindhoven Netherlands.

Katherine Tweden

Dr. Katherine S. Tweden, Ph.D., has been promoted as Senior Vice President - Research of the Company. She was the Vice President - Clinical and Regulatory of EnteroMedics Inc., since May 2011. Prior to that Dr. Tweden served as our Vice President of Research and Clinical from September 2008 to May 2011 and our Vice President of Research from January 2003 to September 2008. From November 2002 to January 2003, Dr. Tweden was a consultant to Venturi Group, a medical device incubator company. From January 2003 through August 2004, Dr. Tweden worked for Venturi Development Inc. as a consultant to us. From July 1997 to October 2002, Dr. Tweden held positions including Director of Research and Vice President of Research for HeartStent Corporation. From September 1990 to June 1997, Dr. Tweden held the positions of Senior Research Scientist and Principal Research Scientist at St. Jude Medical, Inc. Dr. Tweden received a Bachelor of Arts in chemistry from Gustavus Adolphus College and a Master’s degree and Ph.D. in biomedical engineering from Iowa State University.

Tonya Dowd

Ms. Tonya Dowd , MPH, is Vice President - Reimbursement of EnteroMedics Inc. "Dr. Shikora brings extensive experience in bariatric and metabolic surgery, as well as neuromodulation and clinical development expertise that will be invaluable to our clinical, research and commercial development of vBloc Therapy," said Mark B. Knudson , PhD, President and Chief Executive Officer of EnteroMedics Inc. "We are delighted to welcome someone with Scott's skill, reputation and acumen to the executive leadership team as we continue to execute our ongoing clinical and commercial strategies." As Director of Reimbursement Policy and Market Access at Quorum Consulting, Ms. Dowd managed the Reimbursement Policy business unit and developed reimbursement and commercial strategies across Quorum's portfolio of clients in the molecular diagnostics, medical device and biopharma arenas. Prior to joining Quorum Consulting, Ms. Dowd spent nine years at Johnson & Johnson where her innovative reimbursement programs and creative health plan interactions contributed to the successful commercialization of new technologies for the general surgery, oncology, bariatric surgery, urology, gastroenterology, anesthesia, gynecology and otolaryngology franchises. Prior to her tenure at Johnson & Johnson, Ms. Dowd co-founded a reimbursement consulting company and worked for numerous medical device and pharmaceutical companies including Covance Healthcare Economics and Outcomes Research and National Data Corporation (NDC). Ms. Dowd holds an undergraduate degree from the University of Michigan in Health Policy and a Master of Public Health from the University of California Los Angeles.

Anthony Jansz

Mr. Anthony P. Jansz is Director of EnteroMedics Inc., since May 2011. Mr. Jansz served as Chairman of the Australian Institute of Weight Control (“AIWC”), the largest network of bariatric surgery clinics in Australia and a collaboration partner with respect to our commercialization efforts in Australia, from 2008 to March 2011. Mr. Jansz is also a director and shareholder of IWC, the Sydney based clinic of the AIWC, and a director and major shareholder of The Medical Finance Company, which provides finance programs for patients undertaking bariatric procedures in Australia. From 2000 to 2005, Mr. Jansz served as a Managing Director for The Carlyle Group where he established Carlyle’s Venture and Growth Capital funds in Asia. From 1995 to 1998, Mr. Jansz worked for Intel Corporation in several management positions across Australia, New Zealand and Asia, and from 1998 to 2000, Mr. Jansz served as Director, Corporate Business Development for Intel Capital where he established and oversaw investment teams and country investment strategies throughout Asia and sat on a number of investment company boards. Prior to joining Intel, Mr. Jansz spent many years working in the information technology industry at Compaq Computer, Borland International, ComputerLand and Tandy Corporation.

Lori McDougal

Ms. Lori C. McDougal is an Director of the Company. Ms. McDougal has served in an executive capacity in the healthcare industry for more than eighteen years. She served as an Executive Vice President at Optum, Inc., the health services platform of UnitedHealth Group, Inc., from 2013 until 2014. Prior to her time at Optum, she served as Chief Executive Officer of UnitedHealth Group's subsidiary UnitedHealthcare Military & Veterans from 2008 until 2013, and previously served as the Chief Operating Officer of UnitedHealthcare Military & Veterans from 2007 until 2008. Prior to that, she served as Vice President of UnitedHealthcare Medicare & Retirement starting in 2002. Additionally, she served as Vice President of UnitedHealth International from 1998 to 2002 and Vice President of OptumInsight from 1996 to 1998. About EnteroMedics Inc.

Catherine Friedman

Ms. Catherine J. Friedman is Independent Director of EnteroMedics Inc., since May 2007. Ms. Friedman currently is an independent financial consultant serving public and private companies in the life sciences. Prior to that, Ms. Friedman held numerous positions over a 23 year investment banking career with Morgan Stanley. Ms. Friedman held the position of Managing Director at Morgan Stanley from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice at Morgan Stanley from 1993 to 2006. Ms. Friedman serves on the Board of Directors and is a member of the audit committee of XenoPort Inc., a publicly-held biopharmaceutical company that develops product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. Ms. Friedman also serves on the Board of Directors and is the chair of the audit committee and a member of the valuation committee and the governance committee of GSV Capital Corp., a publicly-held investment company that focuses on investments in venture capital backed emerging companies.

Carl Goldfischer

Dr. Carl S. Goldfischer, M.D. is Independent Director of EnteroMedics Inc., since July 2004. Dr. Goldfischer is currently an Investment Partner and Managing Director of Bay City Capital, serving as a member of the Board of Directors and executive committee, and has been with the firm since December 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems Incorporated, a publicly-held biotechnology company focused on developing therapeutic oncology products, where he oversaw financial operations and strategic planning. Since 2009, Dr. Goldfischer has served on the Board of Directors of Epizyme, Inc., a publicly traded biopharmaceutical company, where he also serves as chair of the audit committee. He previously served on the Board of Directors of two other publicly traded companies, MAP Pharmaceuticals, Inc. from 2004 to 2011 and Poniard Pharmaceuticals, Inc. from 2000 to 2012. Dr. Goldfischer also serves on the boards and audit committees of several private companies.

Bobby Griffin

Mr. Bobby I. Griffin is Independent Director of EnteroMedics Inc., since September 2006. In 1998, Mr. Griffin retired from a 25 year career with Medtronic, Inc., where he held various positions, including Executive Vice President from 1985 to 1998 and President of Medtronic’s Pacemaker Business from 1991 to 1998. Since his retirement, Mr. Griffin has been a private investor, managing his own fund of companies as well as serving on the advisory boards of Affinity Capital Management Fund III and IV and Sapient Capital Management Fund, in which he also invests. In addition, Mr. Griffin has served on the Board of Directors of several public companies, including MTS Systems Corporation and Urologix, Inc., and is currently a director of several private companies.

Nicholas Teti

Mr. Nicholas L. Teti, Jr. is Independent Director of EnteroMedics Inc., since May 2007. Mr. Teti currently serves as Chairman of the Board, President and Chief Executive Officer of Suneva Medical, Inc., a privately-held aesthetic medical device company. He also serves as an independent consultant to public and private health care companies. From April 2009 to January 2011, Mr. Teti also served in a consultancy capacity to the Chief Executive Officer of EnteroMedics. From June 2009 to the present, Mr. Teti has served on the board of Health Care Royalty Partners Strategic Advisory (formerly Crown Royalty Partners). From January 2008 to March 2009, Mr. Teti was Chief Executive Officer of Den-Mat, a dental aesthetics company focused on developing non-invasive techniques. Mr. Teti served as Chairman of the Board of Isolagen, Inc., a biotechnology company which develops emergent, novel skin and tissue rejuvenation technologies, from January 2008 to June 2009, and was Chief Executive Officer of Isolagen from June 2006 to January 2008. From 2001 to 2006, Mr. Teti was President and Chief Executive Officer of Inamed Corporation, a healthcare products manufacturer focused on marketing breast implants, dermal fillers to correct facial wrinkles, and devices to treat severe and morbid obesity, including the LAP-BAND Adjustable Gastric Banding System. Mr. Teti served on the board of Inamed during 2001 and was Chairman of the Board from 2002 to 2006. Prior to that, Mr. Teti spent 25 years at DuPont and DuPont Merck where he held a number of senior management positions, including President and Chief Executive Officer of DuPont Pharmaceuticals.

Jon Tremmel

Mr. Jon T. Tremmel is Independent Director of EnteroMedics Inc., since January 28, 2009. Mr. Tremmel has been retired and acting as an independent consultant since 2007. Over the course of his career at Medtronic, Inc., Mr. Tremmel served in a variety of senior management positions, including President of the Neurological Division from 2003 to 2007, President of the Physio Control Division, President of the Tachyarrhythmia Management Division and President of the Interventional Vascular Division. Mr. Tremmel currently serves on the board of Cyberonics, Inc., a publicly-held company that designs, develops and markets implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders, and a number of corporate and civic organizations.